ALVO Stock Recent News

ALVO LATEST HEADLINES

ALVO Stock News Image - zacks.com

ALVO preps for Q2 results as investors eye early U.S. traction for Simlandi and Selarsdi, plus pipeline progress.

zacks.com 2025 Jul 30
ALVO Stock News Image - zacks.com

The average of price targets set by Wall Street analysts indicates a potential upside of 91.1% in Alvotech (ALVO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com 2025 Jul 24
ALVO Stock News Image - zacks.com

Alvotech (ALVO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com 2025 Jul 17
ALVO Stock News Image - globenewswire.com

REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership.

globenewswire.com 2025 Jul 10
ALVO Stock News Image - globenewswire.com

REYKJAVIK,  ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Linda Jónsdóttir as Chief Financial Officer (CFO). Linda is a highly experienced international executive with a strong background in finance and corporate leadership. She has held senior roles across a range of industries, including banking, food technology, transportation, and healthcare. Linda will be based in Iceland. Joel Morales, who has served as CFO of Alvotech since 2020, based in the U.S., has decided to step down to spend more time in the U.S. and prioritize time with his family. He will continue supporting Alvotech in an advisory capacity, to ensure a smooth transition.

globenewswire.com 2025 Jul 10
ALVO Stock News Image - globenewswire.com

REYKJAVIK,  ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (“Ivers-Lee”), a family owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutical sector. While Ivers-Lee will remain a separate legal entity, its operations will be integrated into Alvotech's Technical Operations division, supporting Alvotech's ambitious plans for growth.

globenewswire.com 2025 Jul 09
ALVO Stock News Image - globenewswire.com

REYKJAVIK, Iceland and BURGDORF, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group (“Ivers-Lee”), a family owned business with headquarters in Burgdorf, Switzerland specializing in providing high-quality assembly and packaging services for the pharmaceutical sector. While Ivers-Lee will remain a separate legal entity, its operations will be integrated into Alvotech's Technical Operations division, supporting Alvotech's ambitious plans for growth.

globenewswire.com 2025 Jul 09
ALVO Stock News Image - globenewswire.com

Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by Alvotech S.A. reached 6.73%, crossing above the 5% threshold of the total number of voting rights. The above percentage has been calculated on the basis of 22,484,087 own shares out of 334,038,147 shares in issue to which voting rights are attached.

globenewswire.com 2025 Jul 03
ALVO Stock News Image - globenewswire.com

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company's Annual General Meeting (“AGM”) on June 6, 2023, at the 2025 AGM held on June 25, 2025, four independent board directors each received a stock option grant allowing the purchase of up to 24,784 Alvotech shares.

globenewswire.com 2025 Jul 01
ALVO Stock News Image - globenewswire.com

REYKJAVIK,  ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into a supply and commercialization agreement for AVT10, Alvotech's biosimilar candidate to Cimzia® (certolizumab pegol).

globenewswire.com 2025 Jul 01
10 of 50